

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 19191

**Title:** Metabonomic window into hepatitis B virus-related hepatic diseases

**Reviewer's code:** 01847334

**Reviewer's country:** Japan

**Science editor:** Jing Yu

**Date sent for review:** 2015-05-07 15:39

**Date reviewed:** 2015-05-19 10:20

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

The manuscript entitled "The metabonomic window into hepatitis B virus-related hepatic diseases" is an interesting review of a timely subject. The review summarized the metabolomics studies of HBV related liver diseases. While the authors provide basic coverage of the subject matter, the manuscript can be improved. 1, The authors described metabonomics studies of CHB, HBV related LC, and HBV related HCC on Tables. The authors should discuss the differences among these diseases on metabonomics. Was there good metabolic maker for distinguishing these diseases? 2, In section of Chronic hepatitis B, the authors mentioned metabonomics studies about other liver diseases. The author should more discuss the comparison between CHB and other liver diseases on metabonomics.